Evidence-based clinical practice guidelines for peptic ulcer disease 2026

Abstract In 2026, the fourth edition of the evidence-based clinical practice guidelines for peptic ulcer disease by the Japanese Society of Gastroenterology (JSGE) was revised. These revised guidelines cover epidemiology, hemorrhagic peptic ulcers, Helicobacter pylori eradication therapy, non-eradication therapy, drug-induced ulcers, non -H. pylori , and nonsteroidal anti-inflammatory drug (NSAID) ulcers, remnant gastric ulcers, surgical treatment, and conservative therapy for perforation and stenosis. Although H. pylori infection and NSAIDs use remain two major causes of peptic ulcers, the prevalence and mortality rates of peptic ulcer have been declining due to the widespread use of eradication therapy and development of potent acid-inhibitory drugs in recent years. However, an increasing trend in idiopathic ulcers and ulcers caused by non- H. pylori Helicobacter (NHPH) infection has attracted attention. In this revised edition, therapeutic algorithms for the treatment of peptic ulcers based on H. pylori infection, low-dose aspirin (LDA) or NSAID use, ulcer history, and ulcer complications (e.g., hemorrhage) remain largely unchanged. This edition shows options for H. pylori eradication in various situations compared with the previous edition, and recommends the most effective regimens, regardless of Japanese insurance coverage. In addition, a new flowchart outlining the eradication treatment process has been presented. Compared with the previous version, the main changes in pharmacological treatment have been made: due to its acid-inhibitory characteristics compared with proton pump inhibitors and increased evidence of its efficacy and safety, vonoprazan has now been selected as the first-line treatment for peptic ulcers and NSAID- and LDA-induced ulcers.

Authors

Institutions

Publication Details

Journal
Journal of Gastroenterology
Published
2026-08-24
DOI
https://doi.org/10.1007/s00535-026-02504-3
Primary Topic
Helicobacter pylori-related gastroenterology studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evidence-based clinical practice guidelines for peptic ulcer disease 2026

Daisuke Chinda, Tadayoshi Okimoto, Takahisa Murao, Takao Itoi et al.
Journal of Gastroenterology
Helicobacter pylori-related gastroenterology studies
article

Evidence-based clinical practice guidelines for peptic ulcer disease 2026

Daisuke Chinda, Tadayoshi Okimoto, Takahisa Murao, Takao Itoi, Tomoari Kamada, Daisuke Miyamori, Susumu Eguchi, Kiichi Satoh, Takeshi Kanno, Naoki Konishi, Kazuhiro Mizukami, Hourin Cho, Toshimi Chiba, Akinobu Nakata, Mitsushige Sugimoto, Yuka Hirashita, Aya Sunago, Yuji Mizokami, Eri Iwata, Osamu Dohi, K. Tokunaga, Sachiyo Nomura, Hajime Isomoto, Junichi Iwamoto, Junko Mukohyama, Sumio Watanabe, Satoshi Sato, Yoshifumi Takeyama, Akira Higashimori, Atsushi Takagi, Masanori Ito, Shoko Ono, Ryo Katsumata, Hideki Mori, Jun Watanabe, Hiromi Sekiguchi, Satoshi Kikuchi, Toshio Watanabe, Keigo Misawa, Hideki Ono, Shuhei Yoshida, Satoshi Mochida, Ting Wang, Daisuke Asaoka
article en

Abstract

Abstract In 2026, the fourth edition of the evidence-based clinical practice guidelines for peptic ulcer disease by the Japanese Society of Gastroenterology (JSGE) was revised. These revised guidelines cover epidemiology, hemorrhagic peptic ulcers, Helicobacter pylori eradication therapy, non-eradication therapy, drug-induced ulcers, non -H. pylori , and nonsteroidal anti-inflammatory drug (NSAID) ulcers, remnant gastric ulcers, surgical treatment, and conservative therapy for perforation and stenosis. Although H. pylori infection and NSAIDs use remain two major causes of peptic ulcers, the prevalence and mortality rates of peptic ulcer have been declining due to the widespread use of eradication therapy and development of potent acid-inhibitory drugs in recent years. However, an increasing trend in idiopathic ulcers and ulcers caused by non- H. pylori Helicobacter (NHPH) infection has attracted attention. In this revised edition, therapeutic algorithms for the treatment of peptic ulcers based on H. pylori infection, low-dose aspirin (LDA) or NSAID use, ulcer history, and ulcer complications (e.g., hemorrhage) remain largely unchanged. This edition shows options for H. pylori eradication in various situations compared with the previous edition, and recommends the most effective regimens, regardless of Japanese insurance coverage. In addition, a new flowchart outlining the eradication treatment process has been presented. Compared with the previous version, the main changes in pharmacological treatment have been made: due to its acid-inhibitory characteristics compared with proton pump inhibitors and increased evidence of its efficacy and safety, vonoprazan has now been selected as the first-line treatment for peptic ulcers and NSAID- and LDA-induced ulcers.

Journal of Gastroenterology
Oita University (JP), The Japanese Society of Gastroenterological Surgery (JP)
Good health and well-being
Openalex Percentile: Top 7%
Helicobacter pylori-related gastroenterology studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.